There have been consistent whispers during the Trump Campaign of a national infrastructure deal just around the corner. While the whispers persist, there has not been any strong progression towards improving the national infrastructure. Multiple attempts have been made, but they have all fallen apart due to disagreement on the cost associated, where the cash will come from, and what sectors to prioritize. Typically, the first few years of a presidency are difficult to get alignment on topics. Infrastructure improvement seems to be an agreement on both sides. With the senate now split 50/50, Vice President elect, Kamala Harris’ vote could be the sway necessary to nudge the US infrastructure deal into action. With the American Society of Civil Engineers grading out the United states as a D+ on the current infrastructure, we certainly could use some renovations.
After unprecedented gains in 2020, which were overshadowed by COVID-19, many in the trucking industry are excited about the outlook for 2021. The trucking industry expects to see an increase in sectors such as final-mile delivery, contracting, home improvement, and overall E-commerce. The American Trucking Associations, Chief Economist Bob Costello says, “I think freight will remain decent in 2021. On the good side, the vaccine will help return to ‘normal,’ which means sectors that are currently hurting like services and manufacturing can bounce back”. This is great news for an industry that at the start of this pandemic in 2020 saw sales of Class 8 trucks fall by 24.3% in the first quarter, and 51.2% in the second quarter.
To combat COVID-19, Moderna launched a Phase 1 study consisting of 45 participants in an effort to create a vaccine on an expedited timeline. March 16th was the start of the Phase 1 testing. The initial group of 45 people were divided into groups of 15 individuals. Each grouping received 2 doses of treatment, but each group received a different dosage of the proposed vaccine (25, 100, or 250 microgram dosages). The subjects who received both doses, showed higher levels of virus-defeating antibodies when compared to individuals who had recovered from the coronavirus. The majority of participants who received both dosages did report adverse reactions, as to be expected during the trials.